Mass spectrometry in drug discovery and development

Drug Discovery World

Volumn 11, Issue 4, 2010, Pages 73-85

  Naylor, Stephen ^a,b   Babcock, Paul T ^c  

^a D2D Inc   (United States)

^b MaiHealth Inc   (United States)

^c Marion County Health Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPILLARY ELECTROPHORESIS; COMPUTER PROGRAM; DRUG DEVELOPMENT; DRUG INDUSTRY; ELECTROSPRAY; GAS CHROMATOGRAPHY; ION MOBILITY SPECTROMETRY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; TANDEM MASS SPECTROMETRY;

EID: 78049301774     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. PriceWaterhouseCoopersPharma 2020. I) The vision; ii) Which Path will you Take?; iii) Marketing the Future; iv) Challenging Business Models; v) Taxing Times Ahead. http://www.pwc.com/pharma-life-sciences/pharma-2020/index-html.
2. Naylor, S. Systems Biology: Information, Disease and Drug Discovery. Drug Discov.World. Winter Edition: 23-33 (2004/2005).
3. Naylor, S, Culbertson, AW and Valentine, SJ. Technology-Bane or Bonanza for the Pharmaceutical Industry? Drug Discov.World. Fall Edition: 51-58 (2007).
4. Goodman, M. Pharmaceutical Industry Financial Performance. Nature Rev. Drug Discovery. 8: 927-928 (2009).
5. Pharmaceutical Research and Manufacturers of America (PhRMA). http://www.phrma.org/.
6. Liebman, MN. Personalized Medicine-End of the Blockbuster? Pharma Focus Asia. 9: 4-8 (2008).
7. Naylor, S and Cole, T. Overview of Companion Diagnostics in the Pharmaceutical Industry. Drug Discov.World. Spring Edition: 67-79 (2010).
8. Naylor, S and Cole, T. Companion Diagnostics in the Pharmaceutical Industry: Part II-Business Models. Drug Discov. World. Summer Edition: 61-67 (2010).
9. Jordon, R. (Editor). Insight Back to the Future. Drug Discov.World. Summer Edition-Supplement 1-44 (2010).
10. Accenture Report. The Pursuit of High Performance Through Research and Development Understanding Pharmaceutical Research and Development. http://www.pharma.org/files/Accenture%20R&D%20Report-2007.pdf June 17 (2007).
11. Bains, W. Failure Rates in Drug Discovery and Development: Will We Ever Get Any Better? Drug Discov. World. Fall Edition: 9-18 (2004).
12. Naylor, S. NostraPharmus Revisited: A Future of Splendid Isolation or Multilevel Participation for Pharmaceutical Companies. Drug Discov.World. Summer Edition-Supplement 24-26 (2010).
13. Griffiths, J. A Brief History of Mass Spectrometry. Analy. Chem. 80: 5678-5683 (2008).
14. Gross, ML and Caprioli, R. (Eds).The Encyclopedia of Mass Spectrometry 10 Volume Set. Elsevier Press. 2003-2010.
15. Papac, DI and Shahrokh, Z. Mass Spectrometry Innovations in Drug Discovery and Development Pharm. Research 18: 131-145 (2001). (Pubitemid 32592591)
16. Janiszewski, JS, Liston, TE and Cole, MJ. Perspectives on Bioanalytical Mass Spectrometry and Automation in Drug Discovery. Curr. Drug Metabol. 9: 986-994 (2008).
17. Rossi, DT and Sinz, MW (Eds). Mass Spectrometry in Drug Discovery. Marcel Dekker Inc. 2002.
18. Korfmacher, WA (Ed). Using Mass Spectrometry for Drug Metabolism Studies (2nd Edition). CRC Press/Taylor Francis Group. 2010.
19. De Hoffmann, E and Stroobant, V. Mass Spectrometry: Principles and Applications (3rd Edition) Wiley & Sons 2007.
20. Landers, JP (Ed). Handbook of Capillary and Microchip Electrophoresis and Associated Microtechniques (3rd Edition) CRC Press/Taylor Francis Group 2008.
21. Strategic Directions International Inc. Market Research Report on Mass Spectrometry 2009. http://www.strategic-directions.com/apps/.
22. Marusina, K. Accelerator MS is a Powerful New Tool. Genetic Eng. News 27: 1-3 (2007).